[A25-91] Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax and obinutuzumab) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2025
Project no.:
A25-91
Commission:
Commission awarded on 01.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with previously untreated chronic lymphocytic leukaemia
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-91
| Project no. | Title | Status |
|---|---|---|
| A25-90 | Acalabrutinib (mantle cell lymphoma; monotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-89 | Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-85 | Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-103 | Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-104 | Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-105 | Acalabrutinib (chronic lymphocytic leukaemia; pretreated) - Benefit assessment according to §35a Social Code Book V | Commission completed |